-
-
Invest Shanghai
Bank of China released an action plan in Shanghai on May 7 to support the full-chain innovation and development of China's biomedicine industry, pledging no less than 1 trillion yuan ($147 billion) in comprehensive financial support during the 15th Five-Year Plan period (2026-30).
BOC will focus on major biomedicine clusters, including the Yangtze River Delta region, the Beijing-Tianjin-Hebei region, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing region, helping build an industrial ecosystem supported by policy guidance, technological innovation, and financial services.
According to the Shanghai Municipal Commission of Science and Technology, Shanghai's biomedicine industry exceeded 1 trillion yuan in scale for the first time in 2025, with biomedicine manufacturing output approaching 210 billion yuan.
The industry's global reach continued to expand, with 48 overseas licensing deals, a 55 percent rise from last year, and transaction values jumping 85 percent to $33.76 billion.
BOC plans to establish a financial service system covering the full life cycle of biomedicine companies, aiming to foster more than five globally influential leading enterprises and over 50 specialized and sophisticated companies and industry "hidden champions" in niche sectors.
The bank will utilize its global network to facilitate the international expansion of Chinese-funded pharmaceutical enterprises, enabling the global deployment of their proprietary products and technologies. Concurrently, the bank aims to funnel top-tier global biomedical resources into the domestic market, fostering a seamless integration of international and domestic innovation, industrial, and capital chains.
To address the sector’s high investment, high risk, and long development cycles, BOC has created a specialized product and service system, with an integrated, coordinated cultivation model, and four innovative products, providing full life-cycle coverage from laboratory research to market launch.